Publicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (11)

2024

  1. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

    Nature, Vol. 629, Núm. 8013, pp. 919-926

2022

  1. Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 28, Núm. 8, pp. 1640-1650

2021

  1. Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer

    Trends in Cancer, Vol. 7, Núm. 5, pp. 410-429

2020

  1. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma

    JCI Insight, Vol. 5, Núm. 15

2019

  1. Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance

    Cell Adhesion and Migration, Vol. 12, Núm. 4, pp. 394-397

  2. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

    Cell, Vol. 172, Núm. 4, pp. 857-868.e15

2017

  1. A Braf kinase-inactive mutant induces lung adenocarcinoma

    Nature, Vol. 548, Núm. 7666, pp. 239-243

  2. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma

    Oncogene, Vol. 36, Núm. 16, pp. 2309-2318

2016

  1. KRAS-driven lung adenocarcinoma: Combined DDR1/Notch inhibition as an effective therapy

    ESMO Open, Vol. 1, Núm. 5

2014

  1. Genetic characterization of the role of the Cip/Kip family of proteins as cyclin-dependent kinase inhibitors and assembly factors

    Molecular and Cellular Biology, Vol. 34, Núm. 8, pp. 1452-1459